ライフサイエンスコーパス: dialysis

1 30 ml per minute per 1.73 m(2) or receipt of dialysis).

2 y disease [CKD], 0.5% for stage 5 CKD and no dialysis).

3 alysis (73.6% hemodialysis; 26.4% peritoneal dialysis).

4 ry of patients with initial CN not requiring dialysis.

5 n whites, and are less likely to discontinue dialysis.

6 annsfield, Mass) was partially pulled during dialysis.

7 347 (19%) of the patients with AKI required dialysis.

8 sphorus levels in patients receiving chronic dialysis.

9 d acute kidney injury (AKI) without need for dialysis.

10 age liver disease (MELD) score, and need for dialysis.

11 ic kidney disease, including those receiving dialysis.

12 1.73 m(2) who are not undergoing maintenance dialysis.

13 rbidity and mortality in patients undergoing dialysis.

14 ere available, 70 (2.0%) underwent post-TAVR dialysis.

15 hospitalization, of whom 25 (27.4%) required dialysis.

16 ences in the frequency of discontinuation of dialysis.

17 tients on hemodialysis, and 20 on peritoneal dialysis.

18 orus level among patients receiving incident dialysis.

19 ies compared to 76% of all patients starting dialysis.

20 ified by ammonium sulphate precipitation and dialysis.

21 nicians to better health among minorities on dialysis.

22 ile others were resigned to the drawbacks of dialysis.

23 ar disease are common in children undergoing dialysis.

24 (19.5%) recipients experienced DGF requiring dialysis.

25 arterial mean flow velocity (MFV) throughout dialysis.

26 ted patients with ESKD requiring maintenance dialysis.

27 t higher risk for venous thromboembolism and dialysis.

28 dwelling catheters, or undergoing peritoneal dialysis.

29 risk of death for patients receiving chronic dialysis.

30 edictive of in-hospital AKI and the need for dialysis.

31 tation (KT) compared with those remaining on dialysis.

32 n and body temperature were unchanged during dialysis (1.2 +/- 0.4 vs 1.1 +/- 0.4 L/min; p = 1.0 and

33 ate and the number of patients alive without dialysis) 1 y after transplant.

34 prevalence of vasopressors (50.3% vs 36.9%), dialysis (19.4% vs 10.3%), severe sepsis (20.3% vs 10.3%

35 e identified patients initiating maintenance dialysis (2008-2015) from the US Renal Data System, defi

36 psis (7%), and acute renal failure requiring dialysis (3%).

37 ntilation (20-33%), intubation (15-24%), and dialysis (3-5%) varied according to the query method use

38 s (median age 66 years; 58.2% men) receiving dialysis, 300 (19.6%) developed COVID-19 infection, crea

39 dney injury (25% vs 16%, P < 0.001), and new dialysis (4.3% vs 2.1%, P = 0.003).

40 g 30% in-hospital survival; ventilation 94%, dialysis 56%.

41 289 699 cases with AMI, 1398 (0.5%) were on dialysis (73.6% hemodialysis; 26.4% peritoneal dialysis)

42 22.86-fold increase in the odds of requiring dialysis (95% CI, 2.77 to 188.75).

43 ssess patency-adjusted costs of endovascular dialysis access maintenance by physician specialty.

44 t with congenital aortic atresia and limited dialysis access options presented to our institution for

45 recipient population included pretransplant dialysis (adjusted incident rate ratio [aIRR] 3.26, P =

46 In comparison with those who remained on dialysis, adjusted risk of death 12 months after transpl

47 vs 9.8%; p = 0.018), and more likely to need dialysis after the surgery (10% vs 0%; p = 0.037).

48 into the liposome aqueous core, followed by dialysis against a solution of 300 mOsm L(-1) produces a

49 gs primarily reflect increased likelihood of dialysis among patients without insurance at certain fac

50 We followed 52,936 patients on dialysis and 16,820 transplant recipients for 170,055 an

51 The study excluded 1,083 patients receiving dialysis and 847 discharged on thiazide diuretics.

52 alence estimates according to the overall US dialysis and adult population, and present estimates for

53 ns for the use of GH in children with CKD on dialysis and after renal transplantation.

54 tive SLK recipients, recipient pretransplant dialysis and components of kidney graft quality comprise

55 ating a large demand for isolated outpatient dialysis and inpatient beds.

56 igated using in vitro digestion, equilibrium dialysis and kinetic analyses.

57 ould shape decision-making about hospice and dialysis and made it hard to individualize care; (2) hos

58 We identified all Australian patients on dialysis and patients with transplants from 1980 to 2014

59 ry including 2585 patients >=60 years old on dialysis and placed on the KT waiting list, 1084 receive

60 ogy, the European Renal Association-European Dialysis and Transplant Association and the Internationa

61 logy/European Renal Association and European Dialysis and Transplant Association Registry.

62 nkage between the Australian and New Zealand Dialysis and Transplant Registry (ANZDATA) and national

63 nkage between the Australian and New Zealand Dialysis and Transplant Registry and national death regi

64 ough 2018 from the Australia and New Zealand Dialysis and Transplant Registry.

65 0 to 2014 from the Australia and New Zealand Dialysis and Transplant Registry.

66 (ESPN) CKD-Mineral and Bone Disorder (MBD), Dialysis and Transplantation working groups present clin

67 t unavailability of costly therapies such as dialysis and transplantation.

68 examined the frequency of discontinuation of dialysis and used simulations to estimate survival in mi

69 f the study's 59 patients were on peritoneal dialysis, and 57 were on hemodialysis.

70 ments: mechanical ventilation, vasopressors, dialysis, and cardiopulmonary resuscitation.

71 its, patients on hemodialysis and peritoneal dialysis, and HNE-modified HDL.

72 is (either in-center or at home), peritoneal dialysis, and kidney transplant.

73 ed the rates of ventilation, intubation, and dialysis, and looked for potential errors in the vital s

74 tient, inpatient, emergency, pharmaceutical, dialysis, and total health care costs by eGFR (Kidney Di

75 the zebrafish embryo using TK experiments, a dialysis approach, thermodynamic calculations, and kinet

76 overs remove excess fluid through peritoneal dialysis, aquaphoresis, or hemodialysis.

77 Patients on haemodialysis or peritoneal dialysis are likely to be at increased risk of novel cor

78 to phosphorus control in patients receiving dialysis are unknown.

79 to -1.2%); and, excluding patients receiving dialysis at baseline, AKI occurred in 34 of 145 (23%) vs

80 ety-net reliant were more likely to initiate dialysis at certain facility types.

81 slightly lower relative risks of initiating dialysis at for-profit and non-profit chain-owned facili

82 rom 11% to 14%; 73% of such patients started dialysis at for-profit/chain-owned facilities compared t

83 facilities, and were more likely to receive dialysis at hospital-based facilities.

84 had a 30% higher relative risk of initiating dialysis at nonprofit/independently owned versus for-pro

85 for kidney transplantation within 1 year of dialysis at the 690 dialysis facilities in Network 6 was

86 ases can limit hospital resources, including dialysis availability and supplies; thus, careful daily

87 An age-sex-calendar year-matched dialysis background population from the Swedish Renal Re

88 engineered into nanoparticles (NPs) using a dialysis-based method, with a resulting geometric diamet

89 am quantities of venemycin are isolable from dialysis-based reactors without chromatography, and the

90 rolled participants with heart failure or on dialysis because guidelines do not recommend lipid-lower

91 enrolled in hospice and to have discontinued dialysis before death.

92 spective study of 986 019 adults who started dialysis between 2005 and 2014, according to the United

93 logram, higher creatinine levels and receive dialysis, but had longer duration to withdrawal of lifes

94 The development of dialysis by early pioneers such as Willem Kolff and Beld

95 The findings may have implications for dialysis care in transplant candidates and the design of

96 ntation.Four days prior to presentation, her dialysis catheter (Palindrome; Medtronic, Mannsfield, Ma

97 taly) via the existing right subclavian vein dialysis catheter because of stenosis in the superior ve

98 In addition, exchange of the dialysis catheter via guidewire was performed, without a

99 al procedures, 53 new AVFs, and 50 temporary dialysis catheters were required.

100 Several dialysis center characteristics were associated with red

101 crease access to kidney transplant; however, dialysis center transplant barriers are common, and limi

102 ected a large proportion of patients at this dialysis center, creating service pressures exacerbated

103 adult patients receiving dialysis in a large dialysis center.

104 We surveyed transplant educators in 1694 US dialysis centers about their transplant knowledge, use o

105 Transplant education in dialysis centers can increase access to kidney transplan

106 ive education practice (1.001.111.23) within dialysis centers were associated with increased wait-lis

107 lood before the filter of the extracorporeal dialysis circuit) as first-line treatment for continuous

108 t included 1219 patients attending satellite dialysis clinics found that older age was a risk factor

109 likely to occur among patients on in-center dialysis compared with those dialyzing at home.

110 cement therapies (KRTs, including peritoneal dialysis, continuous KRT, haemodialysis and hybrid thera

111 ure care, avoiding futile dialysis, reducing dialysis costs, shared decision-making in kidney failure

112 us in children undergoing chronic peritoneal dialysis (CPD) around the globe.

113 insurance, more comorbidities, and being on dialysis decreased the probability of waitlisting while

114 significant risk of mortality and long-term dialysis dependence, emphasizing the importance of appro

115 Here we report on the effect of non-dialysis dependent CKD (NDD-CKD) on mitochondrial mass a

116 d from the vastus lateralis (VL) of n=16 non-dialysis dependent CKD patient's stage 3b-5 (NDD-CKD) an

117 s transplanted into a 61-year-old peritoneal dialysis dependent without complication.

118 a retrospective cohort study of survival and dialysis discontinuation among patients on maintenance d

119 whites if minorities had the same pattern of dialysis discontinuation as whites.

120 Survival and dialysis discontinuation frequencies among American Indi

121 To test if racial and ethnic differences in dialysis discontinuation reflected better health, we con

122 sians had substantially lower frequencies of dialysis discontinuation than whites in each hospitaliza

123 Racial and ethnic differences in dialysis discontinuation were present among patients hos

124 moval in a large animal model, but the final dialysis dose delivered needs to be reduced before the t

125 ) can occur during clinical procedures, e.g. dialysis, due to human error or faulty equipment, and it

126 year mortality was associated with increased dialysis duration (> 3 yr) and phosphatemia (> 2.5 mmol/

127 ), kidney allograft failure (P = 0.012), and dialysis duration (P = 0.031).

128 t age, race, cause of ESKD, and mean monthly dialysis duration were most closely associated with phos

129 the patients with suPAR <4.60 ng/ml required dialysis during their hospitalization.

130 ded a two-stage routine screening process at dialysis entry (temperature and symptom check, with poss

131 ower mortality rates than those remaining on dialysis, even if the kidney came from an extremely aged

132 this bioaccumulative behavior, we performed dialysis experiments and determined membrane/water parti

133 Five bicarbonate dialysis experiments were performed.

134 Longer pretransplant dialysis exposure is associated with a higher risk of tr

135 ortality on the association of pretransplant dialysis exposure with transplant survival through Decem

136 age renal failure (including those receiving dialysis), extremely old patients (such as those aged >8

137 hat receives samples from approximately 1300 dialysis facilities across the USA, we tested the remain

138 irment might allow for broader assessment in dialysis facilities and thus optimal delivery of educati

139 edicare and non-Medicare patients treated at dialysis facilities before and after 2011 payment reform

140 d ESKD payment bundle prompted concerns that dialysis facilities facing higher costs might close, dis

141 ntation within 1 year of dialysis at the 690 dialysis facilities in Network 6 was 33.7% (interquartil

142 ) end-stage kidney disease patients from 690 dialysis facilities in the United States Renal Data Syst

143 of nonprofit/independently owned outpatient dialysis facilities may affect safety net-reliant popula

144 n are modestly but significantly lower among dialysis facilities with larger proportions of minority

145 was not associated with increased closure of dialysis facilities, although the likelihood of closures

146 minimize the risk of disease transmission in dialysis facilities, including education of staff and pa

147 Among dialysis facilities, the mean percentage of patients vac

148 Whether this policy change influenced dialysis facility closures is unknown.

149 Dialysis facility closures were uncommon over the study

150 dialysis from 2006 through 2015 and to track dialysis facility closures.

151 s racial and ethnic composition, we examined dialysis facility data reported to the Centers for Medic

152 r the proportion of patients vaccinated at a dialysis facility differs according to the facility's ra

153 We examined four dialysis facility ownership categories according to for-

154 For estimation of a dialyzable fraction, dialysis filtration was conducted.

155 Data from 14 patients undergoing peritoneal dialysis for end-stage renal disease but without cirrhos

156 The requirement of patients on dialysis for regular treatment in settings typically not

157 limited health insurance receive maintenance dialysis has been lacking.

158 a higher incidence of death or initiation of dialysis (hazard ratio, 1.48; 95% CI, 1.04 to 2.11; P =

159 after hospital admission; if associated with dialysis, hospitalization, surgery, or long-term care fa

160 nd outcomes for all adult patients receiving dialysis in a large dialysis center.

161 Whether patients who receive dialysis in a region with a higher rate of dialysis mort

162 he unit and tested for SARS-CoV-2), isolated dialysis in a separate unit for patients with infection,

163 3 randomly selected adult patients receiving dialysis in July, 2020, using a spike protein receptor b

164 iscontinuation among patients on maintenance dialysis in the US Renal Data System after hospitalizati

165 Many patients receiving dialysis in the USA share the socioeconomic characterist

166 hree measures of ESA dose response, sex, and dialysis incidence versus dialysis prevalence.

167 e in the PCr-Pi ratio (+23%; P=0.001) during dialysis, indicating a reduction in intracellular Pi con

168 ted analyses, higher BMI was associated with dialysis initiation and with venous thromboembolism but

169 is more suitable for assessing the timing of dialysis initiation in a Chinese ESRD population than eG

170 Dialysis initiation or alteration is likely unnecessary

171 l barriers to transplantation at the time of dialysis initiation than NHWs, including age >70 years (

172 Median age at dialysis initiation was 64 years, 45% were female, 32% w

173 ysis settings during the 2-year period after dialysis initiation, adjusting for demographic and clini

174 patients with stage 5 CKD who want to avoid dialysis, is guided by patient values, preferences, and

175 ents experienced progressive CKD (defined as dialysis, kidney transplantation, or a 40% decline from

176 patients were older, sicker, and had been on dialysis longer, with more preexisting cardiovascular di

177 Liposome-supported peritoneal dialysis (LSPD) with transmembrane pH-gradient liposomes

178 Background Dialysis maintenance interventions account for billions

179 CKD and kidney replacement planning, 28 for dialysis management, 18 for broad measures, and two pati

180 Nearly half of the metrics were related to dialysis management, compared with only one metric relat

181 s; the mechanism was confirmed by exhaustive dialysis, mass spectrometry, and in vitro evaluation aga

182 ved survival for patients receiving VA-based dialysis may be useful in establishing best practices fo

183 not able to grow in dilute BSK-II medium or dialysis membrane chambers (DMCs) implanted in rats.

184 e presence of Alnus roots but separated by a dialysis membrane for 64 h.

185 an urgent need to develop new approaches and dialysis modalities that are cost-effective, accessible

186 had not qualified for Medicare by the fourth dialysis month.

187 e dialysis in a region with a higher rate of dialysis mortality are a higher risk for transplant fail

188 sis treatment in a state with a high rate of dialysis mortality are at a higher risk for transplant f

189 The effect of state- and period-specific dialysis mortality on the association of pretransplant d

190 Dialysis mortality within states ranged from 128 deaths/

191 lure in states within the lowest quartile of dialysis mortality, compared with an 8% higher risk in s

192 isk in states within the highest quartile of dialysis mortality.

193 vs n = 6, 27% in controls; p < 0.001), more dialysis (n = 16, 36% vs n = 3, 8% in controls; p = 0.00

194 niversal precautions that included masks for dialysis nursing staff.

195 e uninsured or had only Medicaid coverage at dialysis onset and had not qualified for Medicare by the

196 Fluorescence dialysis or Golgi-impregnation labeling showed reduced d

197 kidney failure (defined as the initiation of dialysis or kidney transplantation) and death.

198 42.2%) to graft failure defined as return to dialysis or retransplantation.

199 ive process that is not recorded in national dialysis or transplant registries.

200 tive cohorts of individuals with CKD (not on dialysis or with a kidney transplant): (1) Renal Impairm

201 tcomes, including prolonged ventilation, new dialysis, or early survival, in the general cohort or be

202 cline in the eGFR, initiation of maintenance dialysis, or kidney transplantation.

203 g transfusion, acute kidney injury requiring dialysis, or major vascular complication at 30 days.

204 he 90-day outcome comprising death, need for dialysis, or persistent impairment in kidney function.

205 sed relative risk for 90-day death, need for dialysis, or persistent kidney impairment (odds ratio: 3

206 sustained profound decline in eGFR, chronic dialysis, or transplant).

207 A NYS small dialysis organization comprising approximately 2200 pati

208 001 for each of the comorbidities except for dialysis (P = 0.07) and acute renal failure (P = 0.19).

209 espite a rapid expansion in the provision of dialysis - particularly haemodialysis and most notably i

210 linked these data to information on incident dialysis patients in a national registry.

211 A total of 1,730 peritoneal dialysis patients in the CRC for ESRD prospective cohort

212 termined in 3-year intervals among prevalent dialysis patients in the United States between 1995 and

213 trace metals in 29 incident and 79 prevalent dialysis patients recruited prospectively.

214 sess mortality risk prediction in peritoneal dialysis patients using machine-learning algorithms for

215 If peritoneal dialysis patients with high mCCI (>4) were aged >=70.5 y

216 ries are associated with poor outcomes among dialysis patients, but whether these associations hold i

217 In dialysis patients, the protein beta2-microglobulin (beta

218 k factors for mortality in Korean peritoneal dialysis patients.

219 Acute peritoneal dialysis (PD) is an important low-cost treatment option.

220 ne (3,4-DGE), which is present in peritoneal dialysis (PD) solutions after heat sterilization, activa

221 s with end-stage renal disease on peritoneal dialysis (PD) underwent randomization and crossover to e

222 stage kidney failure who receive peritoneal dialysis (PD).

223 , 8.3% (8.0-8.6) when standardised to the US dialysis population, and 9.3% (8.8-9.9) when standardise

224 When standardised to the US dialysis population, seroprevalence ranged from 3.5% (3.

225 nd race and ethnicity distribution to the US dialysis population, with a higher proportion of older p

226 low early graft function but did not require dialysis posttransplant.

227 litus, and end-stage renal disease requiring dialysis presented to the emergency department with tend

228 litus, and end-stage renal disease requiring dialysis presented to the emergency department with tend

229 response, sex, and dialysis incidence versus dialysis prevalence.

230 ted from residues of the organic matrix by a dialysis probe and were transferred to a stream of water

231 Using longitudinal data from a national dialysis provider, we constructed hierarchical, linear m

232 teristics of this epidemic may be useful for dialysis providers and other institutions providing pati

233 ce of comorbidities in patients with ESKD on dialysis raise concerns that they may have an elevated r

234 cess to kidney failure care, avoiding futile dialysis, reducing dialysis costs, shared decision-makin

235 with high mortality in patients with ESKD on dialysis reinforces the need to take appropriate infecti

236 erm hemodialysis patients is the hallmark of dialysis-related amyloidosis (DRA).

237 orms amyloid fibrils in a condition known as dialysis-related amyloidosis.

238 sembles into amyloid fibrils associated with dialysis-related amyloidosis.

239 aggregation of WT-beta(2)m, which occurs in dialysis-related amyloidosis.

240 loid deposits in the joints of patients with dialysis-related amyloidosis.

241 stress, mineral and bone abnormalities, and dialysis-related factors, such as changes in cerebral bl

242 nts in the HF-HD group were independent from dialysis (relative risk 1.09, 95% CI 0.74-1.61; p=0.81).

243 >=2-fold increase in serum creatinine or new dialysis requirement directly attributed to an immune ch

244 We describe the frequency of AKI and dialysis requirement, AKI recovery, and adjusted odds ra

245 Bicarbonate dialysis results in CO2 removal at rates comparable with

246 a short separation path with continuous mini-dialysis sample collection.

247 y 66.7% (range, 60.1%-71.5%) after the first dialysis session and by 53.3% (range, 30.4%-67.8%) after

248 had been symptomatic when screened before a dialysis session and received an RT-PCR test; 79 (22.2%

249 Video was recorded for a total of 84 dialysis sessions from 40 patients during the course of

250 odel, we compared all-cause mortality across dialysis settings during the 2-year period after dialysi

251 igible for Medicare by their fourth month of dialysis, some never do.

252 Candidates struggled with the limitations of dialysis; some viewed transplantation as an opportunity

253 This was supported by equilibrium dialysis, STD-NMR experiments, and inhibition analysis o

254 ithout the necessity of pre-concentration or dialysis steps.

255 tion, heart failure, chronic kidney disease, dialysis, stroke, inpatient admission), laboratory value

256 Racial and ethnic minorities on dialysis survive longer than whites, and are less likely

257 We aimed to determine if our respiratory dialysis system removes CO2 at rates comparable to low-f

258 We designed a novel respiratory dialysis system to remove CO2 from blood in the form of

259 e phosphate cannot be efficiently removed by dialysis, the resulting hyperphosphatemia leads to incre

260 4 or 5 chronic kidney disease or undergoing dialysis, the upper bound 95% CI for the risk of NSF was

261 transplant age, gender, race, pretransplant dialysis, transplant center, and year).

262 was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR

263 The primary outcome was a composite of dialysis, transplantation, or death due to kidney diseas

264 to a transplant facility, a prerequisite for dialysis-treated patients to access kidney transplantati

265 c patients and of those receiving peritoneal dialysis treatment have increased levels of the glucose-

266 Patients who received pretransplant dialysis treatment in a state with a high rate of dialys

267 ents with the same duration of pretransplant dialysis treatment in a state with a lower mortality rat

268 sphatemia and with prior duration of chronic dialysis treatment, and with organ failure at ICU admiss

269 evaluation of statin therapy in patients on dialysis undergoing arteriovenous fistula placement is w

270 less than 30 mL/min/1.73 m(2) or undergoing dialysis underwent GA MRI two or more times.

271 ients and health care workers in a pediatric dialysis unit after contact with a seropositive patient.

272 may enable investigation of exposure within dialysis units and hence, assessment of current screenin

273 Arteriovenous fistulas placed surgically for dialysis vascular access have a high primary failure rat

274 Patients with very early dialysis (VED, onset <= 3 months) without bilateral neph

275 ation remained independent of adjustment for dialysis vintage (HR, 1.31; 1.13-1.52; P < 0.001).

276 d to prospectively study the associations of dialysis vintage and NT-proBNP with all-cause mortality.

277 End-stage kidney disease and dialysis vintage are characterized by accelerated athero

278 Our study shows that longer dialysis vintage is associated with a higher mortality r

279 Pretransplant dialysis vintage is associated with excess mortality aft

280 Dialysis vintage was associated with an increased risk o

281 tality and if it explains the association of dialysis vintage with posttransplantation mortality in k

282 adjustments for demographics, comorbidities, dialysis vintage, and kidney transplantation, PH was ass

283 n level, history of stroke and hypertension, dialysis vintage, and single-pool Kt/V.

284 nt and donor age, background kidney disease, dialysis vintage, donor hepatitis C virus status, cardio

285 Each additional year of dialysis was associated with a 4% higher risk of transpl

286 m creatinine without change in urine output; dialysis was not required.

287 Recovery of polyphenols after dialysis was significantly high in naturally ripened ban

288 Dialysis was then performed with a novel low bicarbonate

289 During dialysis, we removed 101 (+/-13) mL/min of CO2 (59 mL/mi

290 utcomes of COVID-19 in patients with ESKD on dialysis, we retrospectively collected clinical data on

291 Functional status and dialysis were predictors of posttransplant mortality in

292 ing their first heart transplant, and not on dialysis, were included in study.

293 , nickel, and arsenic increased with time on dialysis while manganese decreased.

294 Patients on dialysis who have an acute myocardial infarction (AMI) h

295 ly collected clinical data on 59 patients on dialysis who were hospitalized with COVID-19.

296 proportion of patients <65 years initiating dialysis who were safety-net reliant increased significa

297 Over the last 18 years, more patients on dialysis with AMI have been treated with evidence-based

298 Compared with patients undergoing dialysis with an arteriovenous fistula, those doing so v

299 , as it implies the need for reinitiation of dialysis with associated morbidity and mortality, reduce

300 nassisted AVF maturation (successful use for dialysis without prior intervention) and overall maturat